# Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

> **NCT03080116** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 90 (actual)

## Conditions studied

- Prostate Cancer
- Neoadjuvant Therapy
- Androgen Antagonists
- Prostatectomy

## Interventions

- **DRUG:** ARN-509
- **DRUG:** Degarelix
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03080116
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-28
- **Primary completion:** 2021-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080116, "Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03080116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*